



FUJIFILM Holdings Corporation

**SUSTAINABILITY  
REPORT**

**2021**

SVP Stories

Contents

Introduction

Technologies and Business Fields .....04  
 Top Management Commitment.....06

Medium- to Long-Term Vision

Bringing about a Sustainable Society through Innovation .....08  
 SVP2030 and Priority Issues .....10  
 Medium-Term Management Plan "VISION2023" .....12

Editorial Policy

- FUJIFILM Holdings Sustainability Report 2021 comprises two parts in response to recent demand for information disclosure. One is Management Performance and the other is SVP Stories. Overviews of each part follow.

	Management Performance	SVP Stories
<b>Report overview</b>	The results of FY2020 activities systematically cover each aspect of ESG (environment, social and governance), based chiefly on data. Additionally, sustainability accounting showing activity results in numerical figures and third-party assurances are shown at the end.	The sustainability scenario is described as concrete actions toward SVP2030. The 2021 edition includes an overview of the activities in FY2020 (Pages 14–15) and special content covering our wide-ranging activities centered on the keywords of the environment, digital transformation (DX) and the COVID-19 pandemic (Pages 16–32).
<b>Improved readability</b>	Tables are used for basic approach, related policies, overview, etc., to make the data provided easier to understand.	The main results achieved with respect to priority issues in fiscal 2020 are summarized in a list and our areas of focus are presented in three special features.

- Our Sustainable Value Plan 2030 (SVP2030) is a long-term plan with the same target year as the Paris Agreement and the SDGs. The plan, which was announced in August 2017 together with our medium-term management plan, VISION 2019, was created based on the CSR issues that have high materiality for both the Fujifilm Group and its stakeholders

Activity Report


Progress of Sustainable Value Plan 2030 (SVP2030) .....14  
 Feature 1: Taking Environmental Action Through Our Business .....16  
 Feature 2: Accelerating Solutions to Social Issues with DX.....23  
 Feature 3: Fighting Against COVID-19 .....29  
 Appraisals and Awards .....33  
 Social Contribution Activities .....34

from the environmental and social aspects out of the three fields of our business activities. In its development, these issues were linked to those of the 17 SDGs that we can contribute.

- To increase accessibility to the topics from the CSR issues, they are associated with the GRI standards. Further, continuous third-party opinion has been consulted on environmental and social data to ensure objective assessment and data accuracy.
- For readers who are interested in more extensive information, visit our website that also contains archived data for the last five years. You can find the Integrated Report in the IR Materials on the FUJIFILM Holdings website. Fujifilm, FUJIFILM Business Innovation and other business companies have their own CSR websites for proactive disclosure of information. For more details on their CSR activities, please refer to each company's official website.
- Please note that FUJIFILM Holdings has obtained independent assurance of the following information.
- For details on the boundaries for each topic, please refer to the following website:  
<https://holdings.fujifilm.com/en/sustainability/evaluation>

**Scope of Independent Assurance**  
 Stakeholder management process for the report / Greenhouse gases emissions [Scope 1 (including CFC), 2 and 3 (Category 1)] / Energy consumption / Volumes of water intake and discharge / Volume of waste generated / Volume of VOC emissions / Data on personnel and labor / Management systems supporting the reporting process

Process of Creating the Report



- Period covered by the report  
 Fiscal 2020 (April 1, 2020–March 31, 2021) is covered in the performance data. With regards to the contents of activities, wherever possible, we have conveyed the most recent trends, including activities in fiscal 2021.
- Organizations covered by the report  
 The Fujifilm Group (FUJIFILM Holdings and all the consolidated companies)  
 ©Major consolidated companies are shown on our website.  
<https://holdings.fujifilm.com/en/about/affiliates>
- Date of publication (SVP Stories in Japanese/English)  
 September/October 2021 (Previous report: October 2020)
- Referenced standards and guidelines  
 ©Japan's Ministry of the Environment: Environmental Reporting Guidelines (2018 Version) / ©GRI: The GRI Sustainability Reporting Standards (core compliance) / ©SASB (Sustainability Accounting Standards Board) ©Japan's Ministry of the Environment: Environmental Accounting Guidelines (2005 Version) / ©ISO 26000: Social Responsibility
- Supplemental information regarding reported matters  
 ©The term "employees" refers to all employees, including managers, general employees and part-time staff. The term "company employees" indicates employees (full-time staff).

# The Fujifilm Group's Commitment

## Our Purpose

### Corporate Philosophy

We will use leading-edge, proprietary technologies to provide top-quality products and services that contribute to the advancement of culture, science, technology and industry, as well as improved health and environmental protection in society. Our overarching aim is to help enhance the quality of life of people worldwide.

### Vision

Anchored by an open, fair and clear corporate culture and with leading-edge, proprietary technologies, Fujifilm is determined to remain a leading company by boldly taking up the challenge of developing new products and creating new value.

### Corporate Slogan

## Value from Innovation

## How We Act

### Charter for Corporate Behavior

Based on the following six principles, the Fujifilm Group respects human rights and maintains compliance with as well as respects the spirit of all laws and international rules in its global business activities. Beyond this, we will take proactive action toward the realization of a sustainable society through innovation, while taking into account the impact of our activities.

1. A Trusted Company
2. Social Responsibility
3. Respect for Human Rights
4. Global Environmental Conservation
5. Vibrant Workplaces
6. Management of Various Crises

### Code of Conduct

In all aspects of our corporate activities, we emphasize compliance and endeavor to create new value. If compliance requirements conflict with business profits or the demands of third parties, we give priority to compliance. An open, fair, and clear corporate culture is the basis for all our activities.

- Respect for Human Rights
- Fair Corporate Activities
- Protection / Preservation of Corporate Assets and Information
- Measures Related to Environmental Issues

## How We Will Achieve Our Purpose

### CSR Plan

### Sustainable Value Plan 2030

With fiscal 2030 as its long-term goal, this plan lays the foundations of the Fujifilm Group's business management strategies for sustainable growth. In this plan, we have set targets in the four priority areas of the environment, health, daily life and work style, as well as in supply chain and governance, the basis of our business activities. These targets serve as guideposts toward our goal of contributing to the realization of a sustainable society through the dual standpoints of resolving social issues through our business activities and considering society and the environment in our business processes.

### Medium-Term Management Plan

### VISION2023


In April 2021, the Fujifilm Group formulated a specific action plan for achieving the goals set forth in the Sustainable Value Plan 2030.

# Technologies and Business Fields

The Fujifilm Group applies advanced proprietary technologies cultivated through the photographic film business to a wide range of business domains. We also combine these with outside technologies through open innovation as we continue to create new value that will bring about a positive impact in society.

## Proprietary Technologies of the Fujifilm Group

Since our founding, we have been accumulating the base technologies to support our business, including organic and inorganic materials chemistry, optical technologies and analytical technologies. Based on these technologies, we have honed our proprietary core technologies, which are central to continuously building up our competitive advantage. By combining these technologies, we provide a wide range of products and services.



## The Fujifilm Group's Business Segments

With the establishment of the medium-term management plan "VISION2023" in fiscal 2021, the business was reorganized into four segments: Healthcare, Materials, Business Innovation and Imaging. We have created a solid business portfolio by generating synergy between these four segments sharing our core technologies.



### Healthcare

Providing a wide range of businesses in the fields of prevention, diagnosis and treatment as a total healthcare company

Medical-use picture archiving and communication system (PACS)

Global market share

**No. 1\***



Medical-use PACS SYNAPSE

#### Medical Systems

Various diagnostic equipment such as X-ray imaging, endoscopes and ultrasound, and medical IT systems for centralized management of diagnostic images and other data

#### Bio CDMO

Process development and manufacturing services for high-quality biopharmaceuticals in growing demand and gene therapy drugs

#### Life Sciences

Total solutions in the fields of iPS cells, culture media and reagents for drug development support

#### Pharmaceuticals

Process development and manufacturing services for next-generation nucleic acid drugs and mRNA vaccines

#### Consumer Healthcare

Functional cosmetics such as the ASTALIFT brand and supplement products



### Materials

Various advanced materials and graphic communication solutions

Protective film for polarizers

Global market share

**No. 1\***



FUJITAC protective film for polarizers

Color photoresists for image sensors

Global market share

**No. 1\***

#### Electronic Materials

Various materials (photoresists, CMP slurries, etc.) used to manufacture semiconductors

#### Display Materials

Materials for LCD panels, organic EL panels and other products

#### Other Advanced Materials

Fine chemicals (advanced chemicals, reagents for research use, etc.), industrial products such as sensor film for touch panels and recording media

#### Graphic Communication

Graphic communication solutions (offset printing equipment, digital printing systems, etc.) and inkjet solutions such as industrial printheads



### Business Innovation

Products and solution services that bring about new changes in work styles, improving productivity and inspiring creativity

Multifunction devices

Market share in sales volume in the Asia-Pacific region

**No. 1\*2**



Apeos C7070

#### Office Solutions

Multifunction devices, printers, consumables and document solutions

#### Business Solutions

Solution-oriented document services tailored to various industries and operations, including system integration, cloud services, management of multifunction devices, and business process outsourcing



### Imaging

Various products and services related to photographs and videos from shooting to printing

Instant photo system

Cumulative worldwide sales volume

Over **50** million units



instax mini 11

#### Consumer Imaging

instax, color films, color paper for photo printing, developing and printing systems, photo printing services and more

#### Professional Imaging

Ultra-high image quality GFX Series cameras, compact, lightweight and high image quality X Series cameras, TV and cine lenses, security lenses, machine vision lenses, projectors and more

\*1 According to a survey by Fujifilm \*2 According to a survey by FUJIFILM Business Innovation



## Top Management Commitment

### Making Contributions with Values That Can Only Be Delivered by the Fujifilm Group as a Company Indispensable for a Sustainable Society

#### Never stop our efforts to resolve social issues, even during the COVID-19 pandemic

The COVID-19 pandemic is showing no signs of slowing down, and continues to deal a significant impact on all aspects of people's lives, living, education and work styles globally. Since the outbreak of the disease in early 2020, all economic activity as well as various initiatives to achieve the SDGs have come to a grinding halt, leaving many to re-examine the roles of business enterprises.

Over the past year, the Fujifilm Group has made all-out efforts in helping the world overcome COVID-19, such as contract manufacturing of active ingredients in vaccine candidates, developing AI-based diagnostic imaging support software for pneumonia, and developing and supplying reagents for detecting new virus mutations. Having reinvented itself from a photographic film company into a corporation with a focus on the healthcare and advanced materials businesses, Fujifilm is now feeling the responsibility of contributing to society through business activities more than ever before. As the world moves toward a post-COVID world, there is a growing "Green Recovery" trend of seizing this opportunity to build a more resilient society, capable of addressing social issues including global warming. As a corporate citizen, Fujifilm will continue to work toward resolving such social issues. I am pleased to confirm that Fujifilm, as a signatory company, will also continue to support the Ten Principles of the United Nations Global Compact in the areas of Human Rights, Labour, Environment and Anti-Corruption. We remain committed to accelerating our efforts in all corporate activities to realize a sustainable society.

#### Making a fresh start with the new medium-term management plan "VISION2023" to achieve goals set out in the CSR plan "SVP2030"

In 2017, Fujifilm drew up the CSR plan "Sustainable Value Plan 2030 (SVP2030)," setting out goals to be

achieved by 2030 in four priority areas (Environment, Health, Daily Life and Work Style) and basis of our business activities (Supply Chain and Governance), to be approached from the perspectives of "resolving social issues through business activities" and "considering society and the environment in our business processes." For the last four years, we have carried out activities based on the medium-term management plan "VISION2019" to enhance a far-reaching business portfolio and established a robust business foundation that is resilient even to the pandemic. The new medium-term management plan "VISION2023" was announced in April 2021 as the next step toward achieving goals set out in SVP2030.

Climate-related initiatives, to be implemented in the area of "Environment," include raising the CO<sub>2</sub> emissions reduction target\* from 30% to 45% across the entire product lifecycle (30% reduction target already achieved in fiscal 2019), and increasing the Company's contribution to reducing CO<sub>2</sub> emissions generated in society from 50 million tons to 90 million tons. The emissions reduction target of 45% has been recognized by the international environmental initiative Science Based Targets (SBT) as WB2°C (well-below 2 degrees Celsius), i.e., science-based targets for achieving the 2°C targets adopted in the Paris Agreement. Furthermore, we have begun our study for a 1.5°C aligned science-based target. Based on these efforts, we continue to enhance scenario analysis in line with the TCFD (Task Force on Climate-related Financial Disclosures) recommendations.

\*Fiscal 2030 targets in reference to the fiscal 2013 level

In the area of "Health," Fujifilm has set the target of expanding the deployment of its AI-based medical products and services from 57 countries and regions in fiscal 2019 to 196 in fiscal 2030 with the eventual goal of their introduction to all countries and regions. We will actively provide technical guidance to physicians and laboratory technicians who handle medical devices in order to enhance medical access and quality of healthcare in regions with poor access to healthcare, thereby resolving regional disparity in healthcare services.

In the area of "Daily Life," as digital transformation (DX) advances in our society, Fujifilm will contribute to

building a safe and secure society and peaceful living, adopting a variety of approaches including developing electronic materials for cutting-edge semiconductors that are essential for the development of 5G, autonomous driving, etc., promoting the introduction of recording media and display materials that facilitate data-oriented society, assisting the digitization of the commercial printing and package printing, and creating products and services in the photographic and videographic fields that enrich our lives.

In the area of "Work Style," Fujifilm will enhance its solution delivery, aiming to offer productivity improvement and work styles that facilitate creativity to some 50 million workers. This initiative will be led by FUJIFILM Business Innovation (formerly known as Fuji Xerox, renamed in April 2021) to literally offer innovation-delivering values to client businesses.

This fiscal year, Fujifilm has established a new management structure to further clarify the roles of management execution and supervision. The Board of Directors is now tasked to monitor whether the Company is acting in line with policies set out in the medium-term management plan, functioning fairly to all stakeholders and operating in a direction consistent with values sought by society. This way, we will apply corporate governance that does not hinder business expansion and boosts transparency.

#### Continuing to grow and offer value in order to generate positive changes in society

The Fujifilm Group is capable of deploying a diverse range of businesses and contributing to resolving a range of social issues from various angles. In order to contribute to society in four priority areas (Environment, Health, Daily Life and Work Style) and accelerate global business deployment, we must further use AI technology and ICT to streamline work processes, create group-wide business synergy and foster diverse human resources who can work relentlessly toward our goals. To this end, in assuming the position of CEO, I have declared my commitment

of (1) accelerating our business growth centered on healthcare and advanced materials areas and improving profitability and efficiency in other business areas, (2) promoting group-wide DX, and (3) developing and reinforcing human resources capable of achieving results in the global arena. Regarding (2), we have already announced the establishment of the Fujifilm Group DX Vision in July 2021 and launched a companywide initiative "All-Fujifilm DX Promotion Program" under my direction to encourage all business divisions to identify and tackle DX issues. I will work on these challenges in the effort to apply Fujifilm Group's strengths to creating social values.

In order to change society for the better, the Fujifilm Group needs to be able to create change constantly. Under the slogan of "NEVER STOP," we will take on challenges and continue growing, so as to further contribute to establishing a sustainable society by providing outstanding value.

September 2021



**Teiichi Goto**  
President and CEO



# Bringing about a Sustainable Society through **Innovation**

The Fujifilm Group's business originated with photographic film, a product for which lots of clean water and fresh air are essential to the manufacturing process. It is also a product which requires customers to "buy on trust," since they cannot try it out beforehand.

Thus, for the Fujifilm Group, environmental conservation and maintaining the trust of stakeholders have been the very foundations of our business activities since the beginning. They are the starting point for our corporate social responsibility (CSR) activities and continue to be passed down within our Group, as the Fujifilm Group's "DNA."

We will contribute to the sustainable development of society by putting our Corporate Philosophy into practice through sincere and fair business activities, never forgetting our starting point.

## The Fujifilm Group's Approach to CSR



### Resolving global environmental and social issues with innovation

We believe creating value through innovation, to resolve issues faced by international society such as climate change, poverty and healthcare and to enrich society as a whole, is the essence of corporate management.

### Impacting society in a positive way through a wide range of businesses

We will provide new value in our diversified businesses to create positive changes in society by combining our proprietary technologies that we have cultivated over the years with advanced technologies such as AI.



### Adequately responding to the expectations of society through stakeholder engagement

Through communication with diverse stakeholders, we will continually reassess whether or not we are adequately responding to the expectations of society. And then, we will contribute to society as a sustainable company.




# SVP2030 and Priority Issues

Under the CSR plan “Sustainable Value Plan 2030 (SVP2030),” which outlines our long-term vision targeting fiscal 2030, we will use leading-edge, proprietary technologies to provide top-quality products and services. By doing this, we will work to resolve social issues through our business activities and contribute to the realization of a sustainable society.


Realization of a Sustainable Society through Value from Innovation

Fiscal 2017: Formulation of SVP2030




## SVP2030 Priority Areas and Priority Issues (Materiality)

Targets are set in four priority areas and in the basis of our business activities via a two-pronged approach: considering society and the environment in our business processes and resolving social issues through our business activities.



Priority Areas	Priority Issues	Resolving social issues through business activities	Considering society and the environment in our business processes	Business Segments	Goals in the SDGs
		Contribution (Opportunities)	Impact (Risks)		
Environment	1. Address climate change 2. Promote recycling of resources 3. Address energy issues toward a decarbonized society 4. Ensure product and chemical safety	●●●●●	●●●●●	▶ Healthcare ▶ Materials ▶ Business Innovation ▶ Imaging	
Health	1. Fulfill unmet medical needs 2. Improve accessibility to medical services 3. Contribute to identifying diseases at an early stage 4. Contribute to health promotion and beauty 5. Promote management of a healthy workplace	●●●●●	●●●●● (Employees)	▶ Healthcare	
Daily Life	1. Contribute to creating a safe and secure society 2. Contribute to enriching humanity and relationships between people	●●●●●	●●●●●	▶ Materials ▶ Imaging	
Work Style	1. Create environments that lead to a motivated workplace (provision of solution services) 2. Develop and utilize diverse human resources	●●●●●	●●●●● (Employees) (Employees)	▶ Business Innovation	
<b>Basis of Business Activities</b>					
● Supply Chain	Strengthen CSR foundations across the entire supply chain including factors of the environment, ethics, and human rights				
● Governance	Improve and maintain governance structures by further disseminating an open, fair and clear corporate culture				


## Process for Identifying Materiality



\* For details of each step, see Section 1.2.4 in the Sustainability Report 2021, Management Performance.


# Medium-Term Management Plan “VISION2023”

In April 2021, we announced our medium-term management plan, VISION2023, which concludes in fiscal 2023. Over the three-year period that began in fiscal 2021, we will invest a total of JPY 1.2 trillion yen to accelerate growth, primarily in the healthcare and advanced materials fields. We will establish a more robust business foundation to enable sustainable growth.



<sup>\*1</sup> Return on equity  
<sup>\*2</sup> Return on invested capital  
<sup>\*3</sup> Cash conversion cycle. Number of days from when payment is made to purchase raw materials to when payment is collected for products or services

<sup>\*4</sup> AI/IT technologies, biotechnology, optical control material technology, etc.  
<sup>\*5</sup> Successor company for diagnostic imaging-related business of Hitachi, Ltd. acquired on March 31, 2021




In our businesses, we share the proprietary technologies we have developed while diversifying our businesses based around photographic film, and the technologies that serve as the foundation for various businesses are connected like the roots of a tree. Through these shared technologies, we are building a business portfolio for realizing groupwide growth by efficiently developing businesses in four domains that appear different at first glance.


Under VISION2023, we seek to further solidify this business portfolio. Our framework for this is accelerating business growth in healthcare and advanced materials and building a more resilient business platform to facilitate sustainable growth. To achieve this, we are promoting the above four priority measures.

In addition to establishing VISION2023, we reorganized our business into four segments (see below). As of fiscal 2021, sales, operating profit and other financial information is disclosed for healthcare as an independent segment. We plan to grow it into our largest segment in terms of revenue and operating income by fiscal 2023.

## Reorganizing into four business segments



Furthermore, for each business categorized as “New/Future Potential,” “Growth Driver,” “Earnings Base” or “Non-core,” we will implement appropriate strategies according to the respective growth phase and reallocate groupwide management resources.



The Fujifilm Group is actively engaging in capital investment and M&A to achieve further growth. Sufficient cash is essential for investment, so we must expand profits and improve our cash generation capabilities. We will engage in a thorough business approach that emphasizes capital efficiency, track the efficiency of each business activity not only by ROE but also by ROIC and CCC, and pursue further improvement of corporate value.

We will also aim to achieve both the improvement of customer satisfaction and cash generation through operations to deliver products at the required time and in the required amount without keeping inventory.



# Progress of Sustainable Value Plan 2030

In fiscal 2020, the Fujifilm Group carried out various activities in line with the Group's CSR plan, "Sustainable Value Plan 2030 (SVP2030)." Here is a summary of activities by materiality in four priority areas and the basis of our business activities.

## Environment

Note: ◎ Excellent ○ Good △ Fair × Poor

Field	Targets for FY2030	Targets	Index	Unit	Results *1			Target value for 2030	Against target	
					2018	2019	2020		Self-evaluation	Progress
1. Address climate change ▶ P. 16-20	Reducing the Fujifilm Group's CO2 emissions	Reduce CO2 emissions across the entire product life cycle*2 by 45% by FY2030, compared to the FY2013 level	Rate for reduction in CO2 emissions	%	23	30	41	45	◎	91%
		Convert 50% of purchased electric power to renewable energy-derived power by FY2030, aiming for zero CO2 emissions from energy use by 2050	Share of renewable energy	%	8	9	9	50	○	18%
	Contributing to reducing CO2 emissions in society through products and services	Contribute to a reduction in the CO2 emissions generated by society by 90 million tons by FY2030	Reduced volume of CO2 emissions	million ton	11	16	20	90	○	23%
Make Green Value Products rate per sales 60% by FY2030		Sales coverage ratio	%	—	27	32	60	○	53%	
2. Promote recycling of resources ▶ P. 21	Reducing the amount of water the Fujifilm Group uses	Reduce the amount of water the Fujifilm Group uses by 30% by FY2030 (compared to the FY2013 level)	Rate of reduction in water usage	%	14	15	16	30	○	53%
	Contributing to water treatment through products and services	Contribute to the treatment of 35 million tons of water per year in society by FY2030	Annual amount of water treatment	million ton	8	5	8	35	○	23%
	Reducing waste	Reduce the amount of waste generated by the Fujifilm Group by 30% by FY2030 (compared to the FY2013 level)	Rate of waste reduction	%	-8	-9	0	30	×	0%
	Improving recycling quality	Achieve recycling index: More than 10 by FY2030	Recycling index*3	—	6.9	6.6	6.5	10	×	65%
Achieve valuables conversion index: More than 1 by FY2030		Valuables conversion index*4	—	0.67	0.67	0.63	1	×	63%	
3. Address energy issues toward a decarbonized society ▶ P. 19	Contribute to the creation and widespread use of renewable energies through advanced materials	New Energy and Industrial Technology Development Organization (NEDO) commenced the development of an "all-solid-state lithium ion battery," a next-generation storage battery for EVs, under an industry-government-academia collaboration. Fujifilm is participating in the project as one of 23 manufacturers of cars and batteries							○	
4. Ensure product and chemical safety ▶ P. 22	Minimize adverse effect of chemical substances on human health and the environment	Completed replacement of two of seven chemical substances within the high priority substances for risk management, a classification newly established in 2020 Held online briefings for business partners and achieved 90% understanding of the chemSHERPA chemical information communication system, contributing to further improvement of management accuracy for hazardous substances used in products							○	

\*1 Some figures have been changed from those listed in FUJIFILM Holdings Sustainability Report 2020 due to a review of the calculation method and scope  
\*2 Including phases such as procurement of materials, and manufacturing, transportation, usage and disposal of products  
\*3 Recycling index = (Recycled volume + Valuable-converted volume) / Simple disposal volume  
\*4 Valuables conversion index = Valuable-converted volume / Recycled volume

New targets set in fiscal 2020

## Health

Priority issues	Targets for FY2030	Major activities	Self-evaluation
1. Fulfill unmet medical needs	Develop and disseminate new treatments based on regenerative medicine and cell therapy	<ul style="list-style-type: none"> <li>Establish a new process development and manufacturing facility for viral vectors and advanced therapies at FUJIFILM Diosynth Biotechnologies in the U.K.</li> <li>Succeeded in propagating the human norovirus using human iPSC-derived intestinal epithelial cells</li> <li>Participated in the Massachusetts Center for Advanced Biological Innovation and Manufacturing, PBLLC, an industry-academia joint research and development consortium in the field of state-of-the-art treatment</li> </ul>	○
2. Improve accessibility to medical services ▶ P. 25,29-31	(1) Reducing burden on medical professionals by utilizing IT	<ul style="list-style-type: none"> <li>Launched pulmonary nodule detection and analysis functions for SYNAPSE SAI viewer, an AI platform, in Japan</li> <li>Launched SYNAPSE Radiotherapy, a radiotherapy planning support software that utilizes AI, in Japan</li> </ul>	○
	(2) Development and dissemination of infectious disease diagnostic system to contribute to global health	<ul style="list-style-type: none"> <li>FUJIFILM Healthcare Corporation newly joined the Fujifilm Group, adding CT, MRI and other devices to the Group's medical equipment lineup, launching higher value-added solutions centered on medical IT globally</li> <li>Manufactured drug substance for COVID-19 vaccine candidates and provided contract manufacturing for COVID-19 vaccine formulation</li> </ul>	
	(3) Offering technical diagnosis training and spreading effective health practices to emerging countries	<ul style="list-style-type: none"> <li>Launched COVID-19 gene detection reagents, gene detection kits and antigen test kits</li> <li>Opened a cancer-focused screening center in India</li> <li>Expanded biopharmaceutical manufacturing facilities at the Denmark facility</li> </ul>	
3. Contribute to identifying diseases at an early stage	Reduce the physical burden through widespread and expanded use of medical diagnostic systems	<ul style="list-style-type: none"> <li>Launched COVID-19 gene detection reagents, gene detection kits and antigen test kits</li> <li>Opened a cancer-focused screening center in India</li> <li>Expanded biopharmaceutical manufacturing facilities at the Denmark facility</li> </ul>	○
4. Contribute to health promotion and beauty	(1) Promote to prolong healthy lives (2) Promote support for women's empowerment	<ul style="list-style-type: none"> <li>Newly developed nanotetrahydropiperine, an ingredient that improves skin elasticity</li> <li>Clearly determined the mechanism by which melanin, which causes age spots, stays in the stratum corneum</li> </ul>	○
5. Promote management of a healthy workplace	Promote management of health and productivity to maintain employees' vitality	<ul style="list-style-type: none"> <li>Held health management e-learning programs for Fujifilm Group employees in Japan</li> <li>Internally published the Declaration of Commitment to Health by Fujifilm Group officers in Japan</li> <li>Incorporated smoking ban during work hours into work regulations</li> </ul>	○

## Daily Life

Priority issues	Targets for FY2030	Major activities	Self-evaluation
1. Contribute to creating a safe and secure society	(1) Develop technologies for products and services and promote their greater use to contribute to the development of ICT society	<ul style="list-style-type: none"> <li>Developed technology to deliver high magnetic tape storage capacity of 580TB using strontium ferrite magnetic particles</li> <li>Enhanced AI-based functions of Fujifilm infrastructure photo analysis service Hibimikke</li> </ul>	○
	(2) Contribute to enhancing the safety of infrastructure through more efficient inspections for the deterioration and malfunctioning of buildings and structures		
2. Contribute to enriching humanity and relationships between people	Contribute to enriching and making people's lives peaceful through records of photos and videos, and photographic products that give form to memories	<ul style="list-style-type: none"> <li>Renewed photobook service Year Album with new personalized functions leveraging AI technology</li> <li>Launched instax SQUARE SQ1, a new entry model compatible with popular square format film</li> <li>Launched mirrorless digital camera FUJIFILM GFX100S with advanced portability and superior image quality</li> </ul>	○

## Work Style

Priority issues	Targets for FY2030	Major activities	Self-evaluation
1. Create environments that lead to a motivated workplace ▶ P. 27	Contribute to generate the innovation for organizations and society by offering solutions and services that support increasing worker's productivity and exerting their creativity	<ul style="list-style-type: none"> <li>Launched the ApeosPort, ApeosPort-VII and ApeosPort Print series, supporting individual work styles by improving operability and convenience and strengthening security</li> <li>Established FUJIFILM RIPCORDER G.K., a service company driving corporate digital transformation</li> <li>Launched provision of IT Expert Service, an outsourcing service helping SMEs to leverage IT</li> <li>Launched Cloud Collaboration Application for DX Suite, a multifunction device application streamlining digitization of paper forms</li> <li>Expanded service locations for CocoDesk private workspace that supports new work styles</li> </ul>	○
		2. Develop and utilize diverse human resources	

## Supply Chain

Priority issues	Targets for FY2030	Major activities	Self-evaluation
Strengthen CSR foundations across the entire supply chain	(1) Realize sustainable procurement considering the environment, ethics and human rights	<ul style="list-style-type: none"> <li>Dissemination of Fujifilm's Code of Conduct, and collection of receipt: 213 companies</li> <li>CSR self-check: Number of suppliers requested and response rate: 568 companies, 75%</li> <li>Percentage of suppliers with 90% or higher conformance rate: 87%</li> <li>Visit and check: Number of suppliers evaluated and plan achievement rate: 56 companies, 90%</li> <li>Supplier response rate for conflict minerals survey and percentage of conflict-free smelters in conflict minerals survey: 99%, 75%</li> <li>Percentage of suppliers fulfilling Fujifilm's paper procurement requirements: 100%</li> </ul>	○
	(2) Ensure compliance with legislation on biodiversity		

## Governance

Priority issues	Targets for FY2030	Major activities	Self-evaluation
Improve and maintain governance structures	Aim for zero cases of misconduct and major legal violations by disseminating an open, fair and clear corporate culture	<ul style="list-style-type: none"> <li>Revision of Corporate Governance Guidelines</li> <li>Establishment of the Fujifilm Group AI Policy</li> <li>Establishment of the Fujifilm Group Global Healthcare Code of Conduct and providing education to employees engaged in related businesses</li> <li>Surveying all Group employees on understanding of Company policies and awareness of compliance</li> </ul>	○



Feature 1



# Taking Environmental Action through Our Business


The Fujifilm Group has regularly highlighted the environment as a key priority within our long-term CSR plan and the medium-term management plan established to meet CSR plan goals. We are addressing environmental issues directly through our business activities and actions.

## Addressing Climate Change


Here is our road map and examples of activities addressing climate change, aiming for carbon neutrality.

The Fujifilm Group will reduce CO<sub>2</sub> emissions by 45% (compared to fiscal 2013) in the entire product life cycle by 2030. By 2050, we aim to eliminate CO<sub>2</sub> emissions in our energy usage (Scope 1 and 2).

Furthermore, by developing and providing energy-saving products and services that help reduce CO<sub>2</sub> emissions, we will promote reduction of CO<sub>2</sub> emissions in society and contribute to the realization of a decarbonized society.



### Road map for reducing CO<sub>2</sub> emissions (Scope 1 and 2)



### Addressing Climate Change Article 1

## Choosing a location for the new facility considering reducing CO<sub>2</sub> emissions: Expanding the sustainable contract development and manufacture of biopharmaceuticals

The Fujifilm Group is expanding its contract development and manufacture of biopharmaceuticals (CDMO\*) business. The Group's core bio CDMO company, FUJIFILM Diosynth Biotechnologies (FDB), has four bases of operations located in the United States, the United Kingdom and Denmark and meets a wide range of customer needs with its advanced production and quality control technologies and state-of-the-art facilities. Because further market growth is expected, FDB announced in March 2021 the new construction of a large-scale cell culture biopharmaceutical manufacturing facility—adding a second facility in North Carolina, USA. The new facility will have eight 20,000 liters bioreactors for cell culture, a large-scale drug product manufacturing line and a packaging line. This will make it possible to provide complete solutions from bulk drug substance to drug product and packaging.

When choosing the location for the new facility, the company took its overall environmental impact on the supply chain into account based on a life cycle assessment, not limited to its own operations. Envisioning supplying products to the United States, which is the highest-demand market, several model cases were used to estimate the CO<sub>2</sub> emissions associated with manufacturing, packaging and shipping. As a result, the company found that all models involving air transport via European manufacturing facilities resulted in tremendous


amounts of CO<sub>2</sub> emissions and that the model of completing all processes within the United States had the least environmental impact. In addition, at the new facility, the company will leverage the advantages of North Carolina's robust state environmental programs such as renewable energy incentives, and will actively introduce systems that reduce environmental impact in collaboration with the local government and its business partners. Going forward, environmentally conscious manufacturing will be expanded, and business growth will be accelerated by utilizing renewable energy sources for all electric power requirements.

\* The Company offers wide-ranging services to pharmaceutical companies, from cell line development to process development, stability testing and manufacturing of investigational new drugs



New FDB facility to be operational in spring 2025 (Holly Springs, North Carolina, USA)

### Model Comparison of Product Supply to the United States




Addressing Climate Change Article 2

## Fujifilm Group “Green Value Products” Certification Program

With the aim of contributing to the realization of a sustainable society, the Fujifilm Group has established the Fujifilm Group “Green Value Products” Certification Program as a mechanism for continuing to create environmentally conscious products and services.

In fiscal 2020, 30 new products were certified, making a total of 166 certified products. We also set a new environmental target for fiscal 2030, “Make Green Value Products rate per sales 60%.” We endeavor to further environmental impact reductions through our products and services.




### Examples of certified products and services

#### Gold certification: Reducing CO<sub>2</sub> emissions in a data-driven society –Magnetic tape and data archiving solution

Currently, the energy required to store enormous volumes of data is a social issue. In hard disk drives (HDDs) used at data centers, the disk continually spins regardless of whether the data is accessed or not, requiring continuous electric power. Fujifilm's data archiving solution can efficiently store “cold data,” which is seldom accessed but said to account for more than 80% of all data. This is because its LTO tape (large-capacity magnetic tape) uses power only when data is written to or read from the tape. It substantially reduces power consumption by approximately 74% compared to storing data on HDDs. This solution was granted a gold certification




for its contribution to reducing energy usage at data centers as the volume of digital data continues to increase.



#### Gold certification: Telecommuting solution “beat” reduces human travel and use of office equipment

Since 2020, telecommuting has been spreading rapidly due to the COVID-19 pandemic, and work styles have been changing. However, there are still many companies that have not adopted it due to concern over security risks. FUJIFILM Business Innovation's telecommuting solution “beat” is a service that provides comprehensive support for secure, simple and convenient network management. It enables a comfortable and safe network environment with its strong security system, a one-stop solution for 24/7 monitoring of network operations, and the flexibility to connect internal and external networks. This solution was granted a gold certification since it reduces the workload of introducing telecommuting, thus contributing to the reduction of CO<sub>2</sub> emissions with less human travel and use of office equipment.



Addressing Climate Change Article 3

## TAC film produces lower CO<sub>2</sub> emissions when disposed of

The Fujifilm Group develops, manufactures and sells triacetylcellulose (TAC) film (product name: FUJITAC), a protective film for polarizers that is indispensable in LCD (liquid crystal display) and OLED (organic light-emitting diode) display polarizers (filters that allow light through only in a specific direction). It has superior optical properties and smoothness as well as high transparency, so it is also used as a substrate for high-performance coating film.


The film is made from cellulose produced from non-edible plants. Around 50% of the CO<sub>2</sub> emissions associated with its disposal are excluded in the total emissions since the emissions from biomass are deducted. For that reason, compared to PET\*1, COP\*2, acrylic and other petroleum-derived films, TAC film is now attracting attention from an environmental perspective as well.

By further expanding the provision of TAC film products, we will contribute to reducing CO<sub>2</sub> emissions in society.


\*1 Polyethylene terephthalate \*2 Cyclic olefin polymer



In 2006, Fujifilm received biomass product certification from the Japan Organics Recycling Association for TAC film.



### CO<sub>2</sub> emissions from waste disposal



Note: CO<sub>2</sub> emissions calculated using general structural formula for each material. Deducted amount for TAC film calculated from biomass material ratio (weight ratio).

Addressing Climate Change Article 4

## Gas separation membrane formation technology contributing to the transition to a decarbonized society

Natural gas emits less CO<sub>2</sub> compared to other fossil fuels such as petroleum and coal, and is considered to be an energy resource that will lead to reduction of CO<sub>2</sub> emissions in the transition period toward the realization of a decarbonized society. The Fujifilm Group has developed and provided CO<sub>2</sub> separation membranes that separate impurities such as CO<sub>2</sub> from natural gas. This process utilizes membrane formation technology leveraging high-precision coating and chemical design technology. By applying these technologies to develop membranes with various properties, we aim to purify and generate energy resources that do not emit CO<sub>2</sub> such as hydrogen. We will continue our efforts to realize decarbonization in the energy domain.



Separation membrane for natural gas purification



Addressing Climate Change Article 5

## Initiatives at each Fujifilm Group site

**FUJIFILM Toyama Chemical Co., Ltd.**

### Reducing CO<sub>2</sub> emissions by converting to city gas

The Toyama Daiichi Plant of FUJIFILM Toyama Chemical converted its fuel for boilers from heavy oil to city gas, resulting in a 1,052-ton reduction in CO<sub>2</sub> emissions per year. Since 2003, the Fujifilm Group has been proactively

converting the fuel for in-house cogeneration systems and boilers from heavy oil to city gas. Now, approximately 90% of the fuel we are currently using is derived from natural gas, which has lower CO<sub>2</sub> emissions.



Fuel equipment at Toyama Daiichi Plant




FUJIFILM Toyama Chemical members

**FUJIFILM Optics Co., Ltd.**

### Four facilities come together to engage in energy-saving activities

FUJIFILM Optics is promoting energy-saving activities companywide. With four facilities each doing their part in improving energy savings, the company reduced its CO<sub>2</sub> emissions by 2,300 tons compared to the previous year. One of the measures is the visualization of power consumption at the Sano Site in Tochigi Prefecture. A fundamental review was conducted on the equipment operating conditions, particularly the air conditioning equipment in the clean room, which accounted for roughly 45% of the department's power consumption. By optimizing the temperature settings and operating times by production area, they were able to reduce their overall power consumption by 16% compared to the previous year.



Energy-savings promotion members

**FUJIFILM Corporation**

### Reducing electric power by improving efficiency of cooling

The Kanagawa Factory of FUJIFILM Corporation supplies the heating and cooling sources used at manufacturing buildings via a central cold water system. In fiscal 2020, power consumption was reduced by further consolidating freezers throughout the worksites and introducing high-efficiency turbo freezers that use inverter control to effectively utilize low-temperature cooling water. For the year, a 240-ton reduction of CO<sub>2</sub> was achieved.




Kanagawa Factory members

## Promoting Environmental Conservation and Recycling of Resources

### Utilizing ICT to prevent problems

#### Faster initial response when water quality changes

The Fujifilm Kanagawa Factory used to respond to night-time problems in the river within the premises only after arriving on site upon getting an emergency call. With improvements, the related data is now managed via ICT and accessed remotely, allowing for quick understanding and response to problems.



#### Monitoring smoke and soot 24/7

At the Fujifilm Fujinomiya Factory, surveillance cameras have been installed to check the conditions of boiler combustion and smoke and soot coming out of the chimney. Monitoring takes place 24/7 at a remote control center.



### Multifunction device certified as Green Design Product in China

DocuCentre-VII C3372 digital color multifunction device was certified as a Green Design Product by the Ministry of Industry and Information Technology of the Chinese government in 2020. It was the first multifunction device of a foreign company in China to be certified as such. In addition, FUJIFILM Manufacturing Shenzhen Corp, which manufactures the product, was certified as a Green Plant in 2019.

The Chinese government is promoting green manufacturing based on the national policy "Made in China 2025" and is certifying Green Design Products and Green Plants. Green Design Products are evaluated based on their environmental impact throughout their life cycle, from product design and development to manufacturing, shipping, use, maintenance and recycling. The Fujifilm device was rated highly for its recycling-friendly design, energy-saving performance and quietness.



Green Design Product certificate

### In-house treatment of wastewater produced when manufacturing conductive film

EXCLEAR is a low-profile, double-sided sensor film for touch panels. Previously, it was difficult to treat the wastewater produced when manufacturing this conductive film, so the process had been outsourced. At the Fujifilm Kanagawa Factory Ashigara Site, acclimatizing active sludge\* to the composition of the wastewater enabled treating all wastewater in house. This reduced the total amount of waste discharged from the factory by around 25% (compared to the previous year).

\* By adding chemicals to the activated sludge a little at a time, microorganisms that break down those chemicals are cultivated, increasing the capacity to break them down.



Ashigara Site members

### Joint wastewater treatment with neighboring companies

At the FUJIFILM Manufacturing Europe B.V. Plant in Tilburg, Netherlands, a large-scale water treatment facility was constructed on the premises in 2016, and it is used jointly with three neighboring companies. It employs the membrane bioreactor treatment method, which is rare in the Netherlands, and is capable of treating 10 million liters of water per day. Purifying wastewater from four companies in a safe and efficient way contributes to reducing the load placed on wastewater treatment facilities in the region.





## Chemical Safety Management

### Contributing to reduction of environmental burden and advancement of R&D such as in pharmaceuticals with a proprietary new peptide synthesis process

The Fujifilm Group launched contract development and manufacturing services for peptides for pharmaceuticals and cosmetics in 2019.


Peptides are protein fragments composed of chains of amino acids. Peptides with the complicated structures required for developing pharmaceuticals and biomaterials are difficult to synthesize using conventional methods, and the amount of solvent used increases in the purification process to increase purity, so there is also a significant environmental burden caused at the time of disposal.

The advantages of the synthesis process developed by Fujifilm over conventional methods include being able to manufacture complex peptides with high efficiency and purity, which enables reducing the amount of solvent to be used and even avoiding use of solvents that could cause cancer or reproductive toxicity.

The Fujifilm Group will contribute to R&D on new pharmaceuticals and biomaterials by providing high-performance, high-purity peptides via its proprietary

process, which itself contributes to reducing environmental burden.

Comparison of amount of solvent used




### Providing technical support to disseminate chemical safety management in ASEAN

FUJIFILM Holdings participates in providing technical support related to the handling of chemical substances in ASEAN, an initiative led by the Ministry of Economy, Trade and Industry (METI) of Japan.

In February 2021, Fujifilm attended a web conference to explain its chemical risk assessment and provide a risk assessment workshop for chemical regulatory authorities and chemical industry associations in both Indonesia and Thailand. This webinar was well received by the attendees for its practical content, which was offered by a company that safely handles a wide range of chemical substances, including reagents, chemical products and high-performance materials.

The Fujifilm Group will continue to take the lead in contributing to ensuring chemical safety in the supply chain, leveraging its knowledge of chemicals management to share necessary skills and systems.



Webinar held for Indonesia

## Feature 2

### Accelerating Solutions to Social Issues with DX

The Fujifilm Group leverages AI and other digital technologies, focusing on the creation of products and services that contribute to digital transformation (DX), which transforms the way society and business work.

#### The Fujifilm Group's Approach

### Tackling mounting medical care issues with medical systems and AI technology

**Toshiyuki Nabeta** (left)  
 Director, Medical Systems Research & Development Center and General Manager, IT Solutions Department, Medical Systems Division, FUJIFILM Corporation

**Masahiro Shimohori**  
 ICT Strategy Division, FUJIFILM Holdings Corporation



#### Contributing to wellness in an age where people live to 100

**Nabeta** In the medical field, issues are emerging in many countries and regions such as increasing medical expenses associated with the aging of society and population growth, regional disparities in medical services and harsh working environments of medical workers. Many of these issues have been exacerbated by the spread of COVID-19. I believe utilization of AI technology is the key to solving these issues.

In the 1980s, Fujifilm introduced the world's first digital X-ray system. Instead of the film-based images that had been used up to that point, we established a system that can produce a digital image on a display. Since then, we have continued to improve our imaging and image processing technologies and evolve our products and services.

By combining these technologies cultivated over many years with the cutting-edge AI technology that is effective in collecting and analyzing tremendous amounts of data, we hope to create products and services that consistently contribute to the healthcare-related fields of prevention, diagnosis and treatment, thereby promoting people's health in an age where people live to 100.

#### Aiming for semi-automated diagnostic imaging workflow

**Nabeta** In April 2018, Fujifilm launched medical AI technology brand REiLI seeking to realize medical systems

that utilize AI technology.

What we aim to do with REiLI is semi-automate the workflows related to diagnostic imaging in particular and provide medical systems that can reduce



physician workloads. The diagnostic imaging workflows through X-rays and CT scans include many steps: (1) examination (imaging), (2) visualization of what was examined, (3) detection of lesions and abnormalities, (4) classification of lesions and abnormalities, and (5) production of image interpretation reports; placing a tremendous burden on medical professionals. At Fujifilm, we have been developing medical systems that utilize AI technology and gradually providing them to medical institutions since 2019 with the aim of reducing that workload (see figure on the next page).

Specifically, we are working on providing solutions that support many aspects of diagnosis by combining various functions, including (1) organ segmentation, which provides stable visualization of organ structure without being affected by individual differences in shape or the presence of disease, (2) computer-aided diagnosis, which automatically detects lesions on the image and helps reduce the risk of them being overlooked and shorten the time required to detect them, and (3) image interpretation reporting workflow, which automatically prepares a draft report based on the lesions specified on the image.



**Shimohori** When the topic of AI comes up, the discussion tends to focus on whether it will or will not exceed human intelligence, but what we aim to do at Fujifilm is support medical professionals through the utilization of AI technology, thereby improving the quality of medical care. The medical professionals who use our products and services understand that point well and have provided feedback that our products and services reduce the risk of overlooking lesions, giving them peace of mind and that they expect to be able to deliver consistent quality of exams and efficient training to develop human resources. The reduction of time spent on interpreting images brings secondary benefits such as being able to spend more time talking with patients.

**Applying the knowledge cultivated in the medical field to other businesses to resolve diverse social issues**

**Nabeta** The technological strength of Fujifilm is that we have both systems such as our X-ray and other diagnostic imaging systems and IT solutions such as our PACS\*1, which contributes to management and sharing of diagnostic images and other medical information and boasts the No. 1\*2 share in the world. Another strength is that we possess a wide range of technologies related to images, including imaging technology and image processing technology.

**Shimohori** Being able to bring together the diverse knowledge and technologies within the Group and apply them in products and services is a distinctive characteristic that sets us apart from our competitors. The automatic production of image interpretation draft reports mentioned earlier was made possible through a collaboration between

Fujifilm and FUJIFILM Business Innovation (formerly Fuji Xerox), which specializes in natural language processing technology (see page 26 for details). Additionally, in March 2021, the Medical Division of Hitachi, Ltd., which commercialized gastric mass screening vehicles and ultrasound diagnostic equipment for the first time in the world, deploying CT, MRI and other such products, was added to the Group as FUJIFILM Healthcare Corporation. The potential for synergy has grown even further.

**Nabeta** We are also working on joint research and joint development with medical institutions, research institutions and start-up companies both in Japan and abroad.

Currently, only a part of the diagnostic imaging workflow can be semi-automated, but our goal for the future is to bring that up to the level where it is the ultimate in AI technology in the medical field or, in other words, giving structure to physician knowledge, through data learning, including quality medical images, and image interpretation reports.

**Shimohori** To use the analogy of cars, the value brought by AI technology is similar to the essential role of car navigation systems that allow you to make it to your destination quickly and reliably. There should be products and services other than medical systems that can be made dramatically more convenient if the processes just before a human makes the final decision can be semi-automated with AI technology. Going forward, we will also set our sights on applying the know-how cultivated in medical systems and AI technology to the various business fields of the Fujifilm Group and further accelerate our efforts as a Group to resolve social issues.

\* 1 Picture Archiving and Communications System  
\* 2 According to a survey by Fujifilm (as of June 2021)



**Medical Products and Services Utilizing AI**


**Utilizing AI technology to implement functions for supporting medical settings**

**Supporting early detection and treatment of lung cancer: Pulmonary nodule detection and analysis functions**

Pulmonary nodules\*1 show up as white shadows on the lungs in X-ray and CT images and indicate the possibility of lung cancer. Lung cancer has one of the highest mortalities among malignant growths (tumors), and it is important to detect pulmonary nodules, which are a symptom, as early as possible for early detection and timely treatment.

Fujifilm utilized AI technology\*2 to develop a pulmonary nodule detection function to support diagnostic imaging for automatic detection of possible pulmonary nodules on CT images of the lungs, and a pulmonary nodule analysis function to analyze pulmonary nodules confirmed by a physician and support the preparation of a report on the physician's findings. These functions are designed to

contribute to reducing the workloads of physicians and streamlining the workflows, and have been available to medical institutions since June 2020 in Japan as applications for Fujifilm's AI platform that supports the diagnostic imaging workflow.



Displaying results of detection of possible pulmonary nodules (Left: Screenshot of whole screen; Right: Enlargement)

**Contributing to the prevention of oversight: Surgical gauze recognition function**

Leaving gauze in the body after a surgical procedure is a serious accident that could result in complications and infections, so medical institutions are seeking technology that will be of use in preventing such oversights.

In May 2020 in Japan, Fujifilm launched a function for recognizing surgical gauze\*3 that supports the confirmation of whether gauze has been left behind in the patient's body after surgery by recognizing and marking surgical gauze in X-ray images using AI technology\*2. It is an option available

with Fujifilm's ultra-lightweight mobile digital X-ray imaging device.





Image showing surgical gauze recognized and marked on a post-surgery abdominal X-ray image

**COVID-19 pneumonia image analysis program**

In certain cases, medical institutions perform CT scans of the chest to go with PCR and antibody tests to check whether a patient has COVID-19 when admitting them to the hospital or providing emergency transport. Reducing the workloads of medical professionals involved in diagnostic imaging has become an issue.

Fujifilm has developed a COVID-19 pneumonia image analysis program utilizing AI technology\*2 to support physicians in diagnostic imaging by indicating the possibility (certainty) that a chest CT image may include radiological findings that are characteristic of COVID-19 pneumonia and marking the areas related to determining the level of

certainty thereof. It was launched as an application for Fujifilm's 3D image analysis system in June 2021 in Japan.



Indicating the possibility (certainty) of a COVID-19 pneumonia finding in three levels on the upper right and marking the area that contributed to the determination of certainty in light blue

\* 1 Refers to growths no more than 3 cm in size, sometimes smaller than 5 mm  
\* 2 Deep learning, which is a form of AI technology, was used in the design. System performance and accuracy do not change automatically once installed  
\* 3 Does not guarantee the recognition of all gauze and requires a comprehensive confirmation including visual inspection of the X-ray

**Development and launch of diagnostic imaging systems based on medical AI technology brand REiLI**

April 2018	April 2019	December 2019	May 2020
<p><b>Announcement of REiLI concept</b></p>	<p><b>REiLI and diagnostic imaging</b></p> <p>Developed SYNAPSE SAI viewer, an AI platform with functions such as automatic organ recognition on CT images, in Japan</p>	<p><b>REiLI and ultrasound diagnostics</b></p> <p>Launched iViz air, wireless ultrasound diagnostic imaging equipment with automatic measurement function for urine volume, in Japan</p>	<p><b>REiLI and X-ray diagnostic imaging</b></p> <p>Launched a function for recognition of surgical gauze as a new option on ultra-lightweight mobile digital X-ray imaging device FUJIFILM DR CALNEO AQRO in Japan</p>
			<p><b>REiLI and X-ray diagnostic imaging</b></p> <p>Launched provision of pulmonary nodule detection function for AI platform SYNAPSE SAI viewer in Japan</p>
			<p><b>REiLI and endoscope diagnostic imaging</b></p> <p>Launched software EW10-EC02 with CAD EYE endoscopic image diagnosis support system that supports endoscopic lesion detection and classification of colon polyps (initially for Europe)</p>
			<p><b>REiLI and X-ray diagnostic imaging</b></p> <p>Launched development of technology to support diagnosis of COVID-19-induced pneumonia in Japan</p>

➤ See pages 25–26 for more information on related products and services.

**Topic** **Development support tool for AI technology assisting diagnostic imaging developed jointly with the National Cancer Center Japan**

Fujifilm developed an AI development support platform with the National Cancer Center Japan to promote research and development of AI technology assisting diagnostic imaging by research and medical institutions (announced in April 2021). This platform facilitates the development of AI technology (software) for assisting diagnostic imaging by physicians and researchers without requiring advanced knowledge of programming. Both parties will utilize the platform in research and verify its usefulness, and Fujifilm will be working on commercialization.



Creating Value through Group Synergy

## Supporting physicians in diagnostic imaging with technology for generating image interpretation reports

Diagnostic imaging via CT scan and other technologies is used in examinations for various illnesses, including COVID-19. Essential steps include the physician inspecting images for lesions or other abnormalities (reading the CT image) and recording the results in a report. In recent years, with advances in imaging devices, it has become possible to obtain many images in a short time, but this has increased the workloads of physicians reading the CT images, which is a challenge at many medical sites.

The technology for generating image interpretation reports jointly developed by Fujifilm and FUJIFILM Business Innovation (formerly Fuji Xerox), along with a pulmonary nodule detection function, allows for automatic detection and analysis of possible lesions and automatic generation of an interpretation draft report based on those results (see flow below). Not only does it reduce the workloads of physicians associated with reading CT images, promoting work-style reform in medical settings, but it also leads to spending more time in communication with patients.


The main technologies supporting the generation of interpretation draft reports are Fujifilm's image recognition technology and FUJIFILM Business Innovation's automatic text generation technology. The former is technology that was cultivated in the photograph and medical equipment

fields and can be used to automatically find images matching a specific description out of an enormous amount of image data. The latter is technology that automates document preparation and summary of the given description using AI. It is based on natural language processing technology\*, which was cultivated in research and development of multifunction devices and other document-related products.

The researchers of both companies formed a project team to establish a new technology based on these while obtaining advice from multiple physicians who read scans on a daily basis. This technology was made possible precisely because the Fujifilm Group possesses knowledge and technologies related to both images and language and has an abundance of connections with medical institutions through businesses such as diagnostic imaging equipment.

Leveraging this technology, Fujifilm began introducing pulmonary nodule detection and analysis functions as applications for AI platform SYNAPSE SAI viewer to medical institutions in June 2020 in Japan. We will continue to promote unified research and development efforts throughout the Group and expand indications.


\* Technology for processing ordinary language used by humans with a computer



The know-how of the automatic text generation technology of FUJIFILM Business Innovation has contributed significantly to improving the fluency of automatically generated draft reports, which makes them feel as natural as ones prepared by humans, and the appropriateness thereof with proper expression of the analysis results without excess or deficiency. We will continue to bring together the diverse knowledge of Group companies as we aim to make our technology for generating image interpretation reports commonplace in medical settings.



Having an abundance of appropriate data is essential for AI learning in order to improve its accuracy. In that regard, Fujifilm has a solid track record in joint research with medical institutions, which has enabled efficient development utilizing a tremendous amount of image data and image interpretation reports from medical cases. We also received cooperation from medical institutions in verifying the appropriateness of the reports to improve the accuracy of the technology. We will seek to apply the technology our team has perfected to fields other than medical systems.



Utilizing DX in Business Process Reform

## Quickly digitalizing paper documents, transforming them into true information assets

Large amounts of contracts, applications, reports and other documents are prepared on a daily basis at various companies and public institutions. In many cases, the originals are still stored in hard copy format, which is one factor that inhibits the sharing and utilization of information. Additionally, many business processes require exchanging paper-based documents, which creates an obstacle when attempting to introduce new work styles such as telecommuting.

FUJIFILM RIPCORDER G.K. was established in September 2020 through a joint venture between FUJIFILM Business Innovation (formerly Fuji Xerox) and US-based Ripcord, Inc. with the aim of solving such challenges. By combining the know-how of FUJIFILM Business Innovation cultivated in business process outsourcing services for converting various paper records\* into electronic format and streamlining work processes with the technology of Ripcord for quickly converting paper documents using robotics technology and AI, we will contribute to reforming business processes involving paper documents.


The service is performed according to the following flow: (1) a dedicated robot scanning paper documents at high speed and high image quality and converting them into digital data, (2) AI automatically tagging and classifying attribute data such as the title using optical character recognition (OCR) technology to facilitate storage, searches and utilization, and (3) managing the data in the cloud.

Processing the information without human involvement reduces the risk of information leaks as well, securely and quickly digitalizing valuable information and releasing it to the customer's workflow.


The scanning process can handle several hundred million pages, far exceeding past services that were available. Another distinctive characteristic is that not only is the information digitalized but it is also automatically categorized and sorted for easier utilization later. For example, digitalizing handwritten application forms used to open accounts at banks and increasing their searchability will help streamline operations at branches and speed up the provision of services to customers. In addition, at insurance companies, digitalizing insurance claims sent from insureds will allow a system in which review work can be performed anywhere. Furthermore, by coordinating with the Medical Systems business of the Fujifilm Group, FUJIFILM RIPCORDER has enhanced its service proposals for streamlining and improving the quality of operations at medical sites, including digitalization of the large amount of paper medical charts remaining at medical institutions.

The company has already begun providing services to several financial institutions in Japan and will gradually roll these services out in Asia, Oceania and other areas overseas.

\* Including estimates, order forms, delivery forms, invoices and receipts



Companies and public institutions in Japan have the same amount of paper documents as their counterparts in the United States, which has a much larger population than Japan. It is said that Japan is 10 years behind in converting these documents into digital data. There is a very good possibility that we can make a contribution in this field. Furthermore, with the urgency of work-style reform, including the introduction of telecommuting, brought on by the COVID-19 pandemic, our role has become even more important. Going forward, in addition to expanding the regions in which we do business, we will enhance our proposals for a wide range of fields faced with the challenge of digitalization.





Establishing a DX Promotion System

## Strengthening the Fujifilm Group's DX platform to accelerate issue resolution


With the target of a corporate transformation leveraging AI and IoT, the Fujifilm Group launched the Strategic ICT (information and communication technology) Promotion Project in 2014, and later in 2017 launched the Digital Transformation Committee comprised of digital officers appointed from each of Fujifilm's divisions. The Group has used these internal organizations as drivers toward solving challenges by leveraging the latest ICTs not only in its business activities but also in all services and operations provided by each of its divisions. Then, in July 2021, Fujifilm adopted the "DX Vision," representing the Group's commitment to further promoting DX to provide products and services of even greater quality than ever before, and to

continuing its work toward resolving social issues. Alongside this vision, the Fujifilm Group newly launched the All-Fujifilm DX Promotion Program, a company-wide DX initiative in which FUJIFILM Holding's President is responsible for the execution. This program establishes project themes within the "foundation" (IT Infrastructure) and each of three "pillars" (Products and Services, Operations, and Human Resources) comprising the Fujifilm Group's DX platform and promotes respective activities. By strengthening this platform, we will not only enable provision of new added value but also increase the speed of our management decision-making, and accelerate our efforts to resolve issues.

### Fujifilm Group's "DX Vision"

Fujifilm's relentless pursuit of a better world is entrenched in the Company's commitment to a more sustainable, healthier, and safer future. We are well prepared for taking on the greatest challenges of our time through the use of advanced and digital technology, valuable and innovative products and services, and from the connected contributions of every business, every team, and every individual at Fujifilm.

### The Fujifilm Group's DX Platform



Topic Establishment of Fujifilm Group AI Policy

AI technology is expected to resolve social issues in various fields, including healthcare. At the same time, its risk of worsening social inequalities and disparities depending on how the technology is applied has also been pointed out. Recognizing these concerns, FUJIFILM Holdings established the Fujifilm Group AI Policy as guidelines for promoting the utilization of AI technology in December 2020. The policy states that we will endeavor to ensure fair use, respect for human rights, management of information security, and transparency for effective and appropriate use of AI technology.

Topic Acquisition of DX certification from METI

The Ministry of Economy, Trade and Industry (METI) of Japan has established a DX certification program to certify companies that have made preparations to promote DX in accordance with the Act on Facilitation of Information Processing. The actions by FUJIFILM Holdings addressing the basic items of the Digital Governance Code, which summarizes actions required of management, including establishment of a management vision for DX, were recognized. In March 2021, the company was selected as a certified DX business operator.



Feature 3

## Fighting against COVID-19

Among the Fujifilm Group's many innovative and significant contributions to healthcare, the company has been engaged in the fight against COVID-19 since the virus began its global spread in 2020. Fujifilm's medical imaging and informatics technologies have aided clinicians in diagnosing and treating symptoms, and the company has been a key manufacturer of pharmaceuticals as well as a contributor to the production of vaccines. Some examples of these activities are summarized here.

Contributing to Prevention of the Spread of COVID-19

### Supporting vaccine development and manufacturing with advanced technology and production control capabilities

Progress is being made worldwide to develop and widely deploy COVID-19 vaccines. Expanding the availability of highly effective vaccines is expected to prevent the spread and reduce the severity of COVID-19, resulting in fewer restrictions on activities and reducing social risks such as the growing strain on healthcare systems. The Fujifilm Group is dedicating its talents, resources and technologies to manufacturing drug substance for vaccine candidates to ensure a steady supply of high-quality vaccines as quickly as possible.

In July 2020, FUJIFILM Diosynth Biotechnologies (FDB), a biopharmaceutical contract development and manufacturing organization (CDMO), was tapped by U.S. biotechnology company, Novavax, Inc., to manufacture the antigen of its NVX-CoV2373 COVID-19 recombinant protein vaccine candidate. The antigen in a vaccine is one of the main components that generate an immune response.

In the same month, FDB began production for Novavax's vaccine candidate at its facility in North Carolina, and its Texas facility began production in December 2020. As part of the U.S. government's Operation Warp Speed, a public-private initiative for the accelerated development and distribution of COVID-19 vaccines and therapeutic drugs, an agreement was signed to secure a portion of

the manufacturing capacity through the end of 2021 at the Texas facility for the Biomedical Advanced Research and Development Authority, an office of the U.S. Department of Health and Human Services. In August 2020, FDB's facility in the U.K. was tapped to manufacture for Novavax's vaccine candidate, with production initiating in February 2021.

In Japan, Fujifilm signed an agreement with biotechnology company VLP Therapeutics Japan (VLP Therapeutics) in October 2020 for the manufacture of a COVID-19 vaccine formulation. This COVID-19 vaccine is a lipid nanoparticle formulation containing self-amplifying RNA (a replicon)\*1 as the active ingredient. Going forward, the Fujifilm Group will utilize its manufacturing equipment and infrastructure, including the lipid nanoparticle manufacturing equipment at FUJIFILM Toyama Chemical's 701 Facility, to take on everything from process development to manufacturing for clinical trials of VLP Therapeutics' COVID-19 vaccine formulations.

\*1 RNA (ribonucleic acid) is a biopolymer composed of a base, sugar and phosphoric acid. It is a type of nucleic acid that governs genetic information. RNA that was added with a function that causes temporary RNA proliferation in vivo after administration is called self-amplifying RNA, or replicon.

Fujifilm Group COVID-19 vaccine development and manufacturing support activities\*2

FUJIFILM Diosynth Biotechnologies U.S.A., Inc. (North Carolina, USA)



Manufacturing of drug substance for NVX-CoV2373 vaccine candidate developed by US-based Novavax launched in July 2020

FUJIFILM Diosynth Biotechnologies Texas, LLC



Manufacturing of drug substance for NVX-CoV2373 vaccine candidate developed by US-based Novavax launched in December 2020

FUJIFILM Diosynth Biotechnologies UK Limited



Manufacturing of drug substance for NVX-CoV2373 vaccine candidate developed by US-based Novavax launched in February 2021

FUJIFILM, FUJIFILM Toyama Chemical



Everything from process development to manufacturing for clinical trials of vaccine formulations developed by VLP Therapeutics Japan

Photo: FUJIFILM Toyama Chemical facility

\*2 As of June 2021



**FUJIFILM Diosynth Biotechnologies plays core role in supporting vaccine manufacturing**

FUJIFILM Diosynth Biotechnologies (FDB) has facilities in the U.K., the U.S., and Denmark and provides the contract development and manufacture of various types of biopharmaceuticals including antibody drugs, recombinant protein, gene therapy drugs and vaccines. Biopharmaceuticals are proteins produced in expression systems composed of living organisms such as animal and insect cells as well as microbial systems such as E. coli, to name a few. As an industry leader with many decades of experience, FDB provides comprehensive services including the development of cell lines, process development, clinical and commercial production of biologics, vaccines and viral vectors.

Fujifilm has a legacy of advanced production technology, cultivated in the photographic film field, including technology for maintaining certain conditions during manufacturing and advanced quality control. Application of Fujifilm's technology to expression technology at FDB has made it possible to increase expression titers and maximize production volumes.

Leveraging these strengths, FDB supports the manufacturing of COVID-19 vaccines and therapeutic candidates thus contributing to the fight against COVID-19.

For more than 30 years, FDB has been supporting partner initiatives to provide vaccines and therapeutic drugs to people all over the world. Our specialized knowledge and capabilities have never been more needed than now during the COVID-19 pandemic. We are currently putting every effort into supporting the manufacture of Novavax's COVID-19 vaccine candidate at our facilities in the U.S. and the U.K.

While addressing this global crisis, FDB will lead the efforts of the Fujifilm Group to resolve social issues in the healthcare field, continuing to provide therapeutic drugs that support the lives and health of patients all over the world without interruption.



**Martin Meeson**  
President and CEO  
FUJIFILM Diosynth Biotechnologies



FDB cellular cultivation equipment offers high productivity



Mobile clean rooms enable a safer and more flexible production system

**Contributing to COVID-19 Diagnosis**

**Responding to changing situations and swiftly providing new PCR test reagents**

The state of COVID-19 infections has been in constant flux, with mutant strains of the virus continuing to emerge; amid this situation, FUJIFILM Wako Pure Chemical Corporation develops and supplies PCR test reagents for research use and other products on short cycles, meeting the needs at hand in this ever-changing environment.

**Enabling quick and accurate saliva PCR tests**

Traditional PCR tests mainly use samples of mucus from the subject's nose or throat. However, insertion of swabs deep into the sinuses causes physical strain on the subject and can put the sample-taker at risk of infection if the subject sneezes or coughs. To address this, FUJIFILM Wako Pure Chemical developed the SARS-CoV-2 Lysis Buffer, a pretreatment reagent that can quickly detect RNA from viruses by only adding the subject's saliva. Furthermore, its SARS-CoV-2 RT-qPCR Detection Kit Ver. 2 (for research use only) prevents false negatives\* caused by the degradation of viral genes in samples, and enables easy, rapid and highly accurate PCR testing.

\* Instances where an infected subject receives a negative test result



SARS-CoV-2 RT-qPCR Detection Kit Ver.2

**Providing reagents identifying mutant strains**

COVID-19 is repeatedly mutating as it spreads throughout the world, altering its pathogenic properties, infectivity and other qualities. In order to identify infection vectors and contain the virus, it is important that PCR tests be able to ascertain the state of infection, including which mutant strain a subject has. FUJIFILM Wako Pure Chemical is continuing to support the fight against these mutant strains by developing and providing a number of kits capable of identifying each of them: the N501Y Mutation Detection Kit for the alpha strain, the E484K Mutation Detection Kit for the beta and gamma strains, and the L452R Mutation Detection Kit and E484Q Mutation Detection Kit for the delta strain (all for research use only).

**Detection of mutated variants (+: Positive, -: Negative)**

	N501Y Mutation Detection Kit	E484K Mutation Detection Kit	L452R Mutation Detection Kit	E484Q Mutation Detection Kit	Detected Variants
SARS-CoV-2 Positive Sample	+	-	-	-	Alpha strain (N501Y)
	+	+	-	-	Beta and Gamma strains (N501Y and E484K)
	-	-	+	-	Delta strain (L452R)
	-	-	+	+	Delta strain (L452R and E484Q)

**Supporting COVID-19 epidemiological studies with PCR tests**

People who are deficient in the Alpha-1-antitrypsin protein (AAT) in the blood due to genetic mutation may be more likely to suffer severe symptoms of COVID-19 infection\*. Using PCR testing to determine possible AAT gene mutation can be useful in epidemiological studies of COVID-19, but it generally takes time to obtain test results. FUJIFILM Wako Pure Chemical used its unique design methods to create the α1-Antitrypsin Gene Mutation (PiS, PiZ) Detection Kit (for research use only), offering an easy and highly accurate way to detect gene mutations. This kit helps provide clarity to the state of COVID-19 infections.

\* The carrier rate of this mutation is said to be high in Western countries.



α1-Antitrypsin Gene Mutation (PiS, PiZ) Detection Kit

**Topic U.S. President and U.K. Prime Minister visit FDB facilities**

In July 2020, then U.S. President Donald Trump visited FDB's North Carolina facility and observed the NVX-CoV2373 drug substance manufacturing equipment, announcing that the U.S. government would contribute roughly US\$265 million to support production. In February 2021, U.K. Prime Minister Boris Johnson visited FDB's U.K. facility. This visit deepened understanding of the technological and production control capabilities of the Fujifilm Group and built anticipation for vaccine availability.

These visits to manufacturing facilities by government leaders showed the social importance of developing vaccines. The Fujifilm Group will continue to work closely with national governments and play a vital role in vaccine production.



Prime Minister Johnson on his visit to FDB's U.K. facility



Contributing to Prevention of the Spread of COVID-19

## Aiming to mitigate infection risk with products using proprietary technologies

The Fujifilm Group continues to develop products in aiming to contribute to preventing the spread of COVID-19, leveraging technologies cultivated in its photography business.

### Antibacterial and antiviral films


Antibacterial and antiviral films are being utilized more and more in touch panels in public facilities and smartphone displays that many people interact with. Fujifilm has developed Hydro Ag+ Virus Plus, an antiviral film for commercial use featuring long-lasting antibacterial and antiviral efficacy using the company's proprietary Hydro Ag+ antibacterial technology. In addition to being affixed to touch panels and other similar screens, this film is also used in splash prevention partitions in medical facilities, convenience stores and taxis in Japan in aiming to reduce viral counts on these surfaces and mitigate infection risk in everyday life.



Example of film usage in a taxi partition




### Ordinary non-hydrophilic membrane silver-based antibacterial coating



Silver ions are released only from the antibacterial agent on the surface

### Structure of super-hydrophilic membranes using the Hydro Ag+ silver-based antibacterial coating technology



Silver ions are constantly supplied to the membrane surface from silver-based antibacterial agent in the membrane

### Reducing burden on medical professionals with anti-fog film

Polyethylene terephthalate (PET) film, found in many ordinary face shields, tends to fog up from breathing or hot air, and suffers from poor transparency and visibility. This has caused problems for medical staff forced to wear them for long periods of time. To address this, the Fujifilm Group supplies processing manufacturers with anti-fog film to be used for face shields supplied to medical institutions. This is a triacetate cellulose (TAC) film boasting high transparency with our unique anti-fog treatment applied. We will continue to provide high value-added products that are helpful to

those working on the medical front lines, utilizing technologies we have cultivated in the field of liquid crystal display materials.



A face shield with anti-fog film

### Topic Fujifilm awarded certificate of gratitude by METI for boosting production of medical supplies

The Ministry of Economy, Trade and Industry (METI) presented a certificate of gratitude to FUJIFILM Toyama Chemical Co., Ltd., FUJIFILM Wako Pure Chemical Corporation and FUJIFILM Wako Chemical Corporation for increasing production of the anti-influenza drug Avigan® and alcohol sanitizers. This certificate of gratitude is given to companies and organizations swiftly increasing production and greatly contributing to the stability of people's lives in Japan in response to the growing demand for medical supplies, driven by the COVID-19 epidemic.



Three group companies awarded at the ceremony

# Appraisals and Awards

### Ranking and status of SRI audit

FUJIFILM Holdings has received the following evaluations by external organizations as a corporate group that proactively promotes CSR actions toward sustainable development. It is also included in the Socially Responsible Investment (SRI) indices listed on the right. (As of June 2021)

Survey	Evaluation for FUJIFILM Holdings
15th CSR Corporate Ranking (2021, Toyo Keizai, Inc.)	3rd out of 1,614 companies (571.2 points)
CDP	Climate Change A- Water A Supply Chain (Supplier Engagement Leader) A
2nd ESG Finance Awards Japan, Environmentally Sustainable Corporations category (Ministry of the Environment)	Committee Chair Award (Bronze)

FTSE4Good Global Index	FTSE Blossom Japan Index
MSCI Japan ESG Select Leaders Index	S&P/JPX Carbon Efficient Index
CDP Water Security A List	CDP SUPPLIER ENGAGEMENT
2nd ESG Finance Awards Japan, Environmentally Sustainable Corporations category (Bronze)	Somo Sustainability Index
DX certification	The 24th Environmental Communication Awards, Judging Committee Special Award for Excellence
2021 Health and Productivity Stock	Sports Yell Company 2021

\* Please refer to the following website for each index.  
<https://holdings.fujifilm.com/en/sustainability/evaluation>

### Appraisals and awards in FY2020

Recipient	Description	Awarding entity
FUJIFILM Holdings Corporation	Received the Judging Committee Special Award at NIKKEI Smart Work Awards 2021	Nikkei Inc.
FUJIFILM Holdings Corporation	First time selected for Health and Productivity Stock Program	Ministry of Economy, Trade and Industry, Tokyo Stock Exchange
FUJIFILM Holdings Corporation and 18 other Group companies	19 Fujifilm Group companies certified as Health and Productivity Enterprises	Ministry of Economy, Trade and Industry
FUJIFILM Toyama Chemical Co., Ltd, FUJIFILM Wako Pure Chemical Corporation, FUJIFILM Wako Chemical Corporation	Certificate of gratitude received for increased production of Avigan® Tablet, an anti-influenza drug, and alcohol sanitizers during the COVID-19 pandemic	Ministry of Economy, Trade and Industry
FUJIFILM Corporation	27 products received the 2020 Good Design Award, and four of them were selected for inclusion in Good Design Best 100	Japan Institute of Design Promotion
FUJIFILM Corporation	23 products received the iF Design Award 2021, the highest number ever	iF International Forum Design
FUJIFILM Corporation	29 products received the Red Dot Design Award 2021, the highest number ever. FUJIFILM PROJECTOR Z8000, an ultra-short throw projector, won the Best of the Best Award	Design Zentrum Nordrhein Westfalen
FUJIFILM Corporation	The product design of compact digital X-ray cart system FUJIFILM DR CALNEO AQRO (FDR nano) received the Minister of Economy, Trade and Industry Award, and the Invention Implementation Achievement Award at the National Invention Awards 2020	Japan Institute of Invention and Innovation
FUJIFILM Corporation	Received the 2020 Minister of Agriculture, Forestry and Fisheries Award for achievements in research and development in agriculture, forestry and fisheries (private sector) in relation to the development and implementation of a foot-and-mouth disease antigen detection test kit	Ministry of Agriculture, Forestry and Fisheries, Japan Association for Techno-Innovation in Agriculture, Forestry and Fisheries
FUJIFILM Corporation	Received the Minister of Economy, Trade and Industry Award at the 19th Green Sustainable Chemistry Awards for development of SUPERIA ZN-II, a completely process-less printing plate for newspapers	Japan Association for Chemical Innovation
FUJIFILM Kyushu Co., Ltd.	Received the FY2020 Commendation for Factories with excellent energy management and the Minister's Award from the Minister of Economy, Trade and Industry and was issued the "Kumamoto Prefecture Forest Absorption Certificate"	Ministry of Economy, Trade and Industry, Kumamoto Prefecture
Fuji Xerox Co., Ltd.*1	Received the 2020 Good Design Award for the ApeosPort, ApeosPort-VII and ApeosPort Print series and historical document reproduction and restoration service	Japan Institute of Design Promotion
Fuji Xerox Co., Ltd.	Received the 2020 Nikkei Superior Products and Services Award and the Nikkei Business Daily Award for the CocoDesk personal workspace	Nikkei Inc.
Fuji Xerox Co., Ltd.	Received the Encouragement Award at the 3rd EcoPro Awards for Iridesse™ Production Press	Sustainable Management Promotion Organization
Fuji Xerox Co., Ltd.	Earned No. 1 rating in the J.D. Power 2020 Color MFP Customer Satisfaction Survey (SM)	J.D. Power Japan, Inc.
FUJIFILM (China) Investment Co., Ltd.	Received the CSR China Education Award	Central Committee of the Communist Youth League
FUJIFILM (China) Investment Co., Ltd., Fuji Xerox (China) Ltd.*2	Received the Foreign-Invested and Hong Kong, Macao, and Taiwan-Invested Enterprise Award and the Evergreen Award: One-Star at GoldenBee CSR Report Honor Roll 2020 (respectively)	China Sustainability Tribune
Fuji Xerox Korea Company Limited*3	Obtained CCM (Consumer Centered Management) Certification	Korea Fair Trade Commission, Korea Consumer Agency

\*1 now FUJIFILM Business Innovation Corp. \*2 now FUJIFILM Business Innovation (China) Corp. \*3 now FUJIFILM Business Innovation Korea Co., Ltd.



# Social Contribution Activities

The Fujifilm Group emphasizes ongoing relationships with local communities as a corporate citizen. We are engaged in activities that take advantage of the nature of our business, such as the provision of medical equipment to emerging countries and disaster sites, the reproduction and utilization of historical documents, and the provision of support through photographs. In addition, we carry out activities all over the world aimed at coexistence with communities, including support for recovery and reconstruction in disaster areas and educational support.

Fujifilm Group Social Contribution Policy  
<https://holdings.fujifilm.com/en/sustainability/vision/policy/society>  
 \* See also Section 4.6 Corporate Citizenship in the Sustainability Report 2021, Management Performance.

## China

### Reforestation activities since 1998: Providing an online program for raising awareness of forest regeneration in 2020



In response to the COVID-19 pandemic, FUJIFILM (China) Investment Co., Ltd. continued its volunteer tree planting activities in the Inner Mongolia Autonomous Region online and provided an educational program for raising awareness of forest regeneration via an app. Additionally, a donation was made to partner non-profit organization Greening Network, funding the planting of 300 trees.

## Portugal

### Communicating the message for preventing breast cancer worldwide via social media



During Breast Cancer Awareness Month in October 2020, FUJIFILM Europe GmbH – Sucursal em Portugal partnered with non-governmental organizations such as the Portuguese League against Cancer to organize "Pink Day," in which employees wore pink to participate. The selfies of all employees wearing pink masks were published in a short animation on the corporate page on business social media platform LinkedIn, making a worldwide appeal for breast cancer prevention and early diagnosis.

## Vietnam

### Organizing an auction for local school flood relief



FUJIFILM VIETNAM Co., Ltd. held an auction to support Ba Long Primary and Secondary School in Quang Tri Province, which was damaged by the major flood in October 2020. All the money raised at the event was donated for the purchase of desks and chairs to support the reopening of the school.

## United States

### Conducting environmental conservation activities in communities via #FujifilmCares Fall Volunteer Events



Employees from Fujifilm's five Group companies in North America with bases of operation in New York and South Carolina carried out beautification activities such as picking up trash and planting seasonal flowers in public parks. A donation was also made for environmental conservation activities, and partnering with a local cleanup campaign, the companies carried out volunteer activities to give back directly to the community as "good neighbors."

## United States

### Holding events to prevent sickness during American Heart Month in February and participating in fundraising



Group companies in North America held internal events for preventing heart attacks and strokes, and more than 300 employees took the pledge of maintaining healthy lifestyles as a new initiative. In addition, Americas region employees raised over 30,000 U.S. dollars through fundraising and walking events. With company matching, a total of 42,322 dollars was donated to non-profit partners such as the American Heart Association.

## Introducing female scientists and powerful women from around the world



The February and July 2021 issues of Women4Women Magazine, which is published by FUJIFILM Europe GmbH, included a special feature introducing female scientists and powerful women from around the world who are experts at the Fujifilm Group or partner with the Group. The February issue highlighted the contributions of women to science in commemoration of International Day for Women and Girls in Science. The July issue focused on exciting experiences based on key words such as commitment, resistance and focus.

February 2021: [https://www.fujifilm.it/women4women/second\\_issue/](https://www.fujifilm.it/women4women/second_issue/)  
 July 2021: [https://www.fujifilm.it/women4women/third\\_issue/](https://www.fujifilm.it/women4women/third_issue/)

## United Kingdom

### Supporting online learning with content that communicates the joy of science to children



To support home learning, which has increased as a result of COVID-19, FUJIFILM UK Ltd. launched an online learning hub for 5-8 year old children to learn about the science that powers Fujifilm technologies from photographs to vaccines. Educational coloring books to reengage children with learning in a fun and exciting way were distributed to elementary schools in the local community and also made available for free download online. Since then, translated books have also been created in Turkey and Germany. In addition, FUJIFILM Diosynth Biotechnologies created a game app called Virtual Victor for children to learn more about gene therapy.

<https://www.fujifilm.com/uk/en/learning-hub>  
<https://fujifilmdiosynth.com/kids-science-portal/>

## Support activities during the COVID-19 pandemic

### Japan



With the cooperation of non-profit Single Mothers Forum, the Fujifilm Group supported around 2,100 single-parent households every month during the period from December 2020 to March 2021. In addition to donations totaling JPY 21 million for the purchase of necessities, Fujifilm disinfecting products and cosmetics were supplied.



Through an NPO, National Children's Cafeteria Support Center, Musubie, the Fujifilm Group donated instax mini 11 instant cameras and film and disinfecting products to 200 children's cafeteria groups nationwide, supporting important community network.

### Singapore



Fuji Xerox Singapore (now FUJIFILM Business Innovation Singapore Pte. Ltd.) partnered with non-profit TOUCH Community Services in volunteer activities to deliver meals to homebound elderly who were unable to go out due to COVID-19.

### India



FUJIFILM India Private Limited partnered with the Society of Indian Radiographers to expand support for growing poverty among underprivileged women during the COVID-19 pandemic. In addition to providing soap, menstrual pads, and other hygiene products, a workshop was held to educate people on breast cancer.

### United States



FUJIFILM Holdings America Corporation and FUJIFILM North America Corporation matched employee donations to provide a total of 20,000 dollars to non-profit Project HOPE for the provision of ventilators, personal protective equipment (PPE), and training to healthcare workers in areas with insufficient service due to COVID-19.

### Australia



As a corporate member of non-profit Australian Business and Community Network, which supports education, Fuji Xerox Australia (now FUJIFILM Business Innovation Australia Pty Ltd.) donated 150 used laptops to four high schools to help eliminate the digital divide that has become more apparent due to COVID-19.



## About the cover page



Sustainability Report SVP Stories

The “I” and “F” in the middle of the FUJIFILM corporate logo have been given an edgy touch to express our commitment to advanced technology. Using this as the motif, we combined it with the six colors used in our CSR plan, Sustainable Value Plan 2030, to emphasize our efforts to resolve social issues with our advanced technology.

## Information Disclosure Tools

### Governance

#### Corporate Governance

<https://holdings.fujifilm.com/en/about/governance>

- Corporate Governance Guidelines
- Report on Corporate Governance
- Fujifilm Group Tax Policy

### Economic aspects

Disclosed as IR information (including governance)

#### Investor Relations

<https://ir.fujifilm.com/en/investors.html>

- Integrated Report
- Securities Report (“Yukashoken Hokokusho”)

### Social/Environmental aspects

Disclosed as CSR information (including governance)

#### Sustainability

<https://holdings.fujifilm.com/en/sustainability>

- Sustainability Report 2021  
SVP Stories / Management Performance
- Site Report



Sustainability Report  
Management Performance

#### GRI Standards Comparison Table

<https://holdings.fujifilm.com/en/sustainability/search>

Please let us know your comments on this report and our sustainability activities via the form below:

<https://holdings.fujifilm.com/en/contact>

## FUJIFILM Holdings Corporation

ESG Division

7-3, Akasaka 9-chome, Minato-ku, Tokyo 107-0052, Japan  
Tel.: +81-3-6271-2065 Fax: +81-3-6271-1190